The study, conducted by researchers in Turkey, comprised 68 adult patients undergoing ambulatory anorectal surgery who were classified as American Society of Anesthesiologists physical status I and II. The patients were split into two groups: Group one received 5 mg of hyperbaric bupivacaine 0.5 percent, and group two received 3 mg hyperbaric bupivacaine 0.5 percent. Both groups were composed of individuals with similar demographics and surgical characteristics.
The study found that the lower dose in group two resulted in a longer sensation-loss time and a shorter duration of time for the sensation to come back. Additionally, group two experienced a shorter voiding time and discharge times.
Improved recovery outcomes and an ideal surgical state suggests the lower dose may be more efficient for patients undergoing ambulatory anorectal surgery, according to the study.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.